Survival benefits of combined-modality treatment in elderly patients with NSCLC
This article has no abstract so we have provided the first paragraph of the full text.
Combined-modality therapy offers survival benefits over radiotherapy alone for patients with non-small-cell lung cancer (NSCLC). Elderly patients have been under-represented in trials of these treatments, however, and no trial has yet directly compared radiotherapy alone with radiotherapy plus chemotherapy in elderly patients with stage III NSCLC. Elderly patients exposed to aggressive combined-modality treatment might be vulnerable to high toxicity and poor outcomes.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.